Alternatively spliced Tissue Factor synergizes with the estrogen receptor pathway in promoting breast cancer progression

Por Kocatürk, B., Tieken, C., Vreeken, D., Ünlü, B., Engels, C.C., de Kruijf, E.M., Kuppen, P.J., Reitsma, P.H., Bogdanov, V.Y., Versteeg, H.H.
Publicado no J Thromb Haemost (2015)

Comment on: The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer

Por Mesker, W E, Dekker, T J A, de Kruijf, E M, Engels, C C, van Pelt, G W, Smit, V T H B M, Tollenaar, R A E M
Publicado no Br J Cancer (2015)

Contralateral breast cancer risk in relation to tumor morphology and age—in which patients is preoperative MRI justified?

Por de Glas, N. A., Engels, C. C., Bastiaannet, E., van de Water, W., Siesling, S., de Craen, A. J. M., van de Velde, C. J. H., Liefers, G. J., Merkus, J. W. S.
Publicado no Breast Cancer Res Treat (2015)

Validity of the online PREDICT tool in older patients with breast cancer: a population-based study

Por de Glas, N A, Bastiaannet, E, Engels, C C, de Craen, A J M, Putter, H, van de Velde, C J H, Hurria, A, Liefers, G J, Portielje, J E A
Publicado no Br J Cancer (2016)

Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma

Por Engels, C C, Fontein, D B Y, Kuppen, P J K, de Kruijf, E M, Smit, V T H B M, Nortier, J W R, Liefers, G J, van de Velde, C J H, Bastiaannet, E
Publicado em 2014

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy:...

Por Engels, C. C., Charehbili, A., van de Velde, C. J. H., Bastiaannet, E., Sajet, A., Putter, H., van Vliet, E. A., van Vlierberghe, R. L. P., Smit, V. T. H. B. M., Bartlett, J. M. S., Seynaeve, C., Liefers, G. J., Kuppen, P. J. K.
Publicado no Breast Cancer Res Treat (2015)